Idiopathic pulmonary fibrosis: state of the art for 2023
The DOI matches its Crossref record; 188 of the 196 references it cites were found in a registry or an index.
Abstract
Review noting that IPF is a progressive fibrotic lung disease characterized by worsening respiratory symptoms and physiological impairment, while the individual patient course and rate of disease progression are often unpredictable and heterogeneous.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to now, the specific therapeutic drugs that reverse IPF or halt the progression of IPF are still unavailable due to the incomplete understanding of the pathogenesis of IPF 5.”
From Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice (2024) · cites this paper as [5]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation
Research works printed but not linked: 1
- 10.1186/s12931-019 · doi:10.1186/s12931-019
Cited by
Items 301–354 of 354
Wang, Y., Wang, J., Lu, R., Zhu, Y., Li, B., & Gao, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s592770
“10 However, lung transplantation is only available for specific patients.”
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
A generative AI framework for disease-specific lung microtissue bioengineeringPreprint
Bahry, E., Pestoni, J. C., Hirzel, K., Savchyn, T., Porras-Gonzalez, D., Getmanchuk-Zaporoshchenko, V., Gregor, M., Conlon, T. M., Yildirim, A. Ö., Harrington, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.15.718723
“Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (PF), and asthma, continue to pose significant health burdens globally 1–3 .”
Zhou, T., He, X., Ju, X., Zhang, C., Fang, H., Liu, Y., Wang, J., Yang, C., & Guo, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1821397 · Cited by 1
Jouneau, S., Prévot, G., Constantin, A., Agard, C., Gauthier, S., Bouvard, C., Guillotin, M., Gorayeb, C., Hakibilen, C., & Aguilaniu, B. (2026) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2026.03.001
Mu, X., Zeng, C., Liu, H., Sun, X., Cao, Y., Wu, M., Yin, T., Su, Y., Zhao, J., Wu, T., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115097
Feng, Z., Takashima, T., Nagata, H., Shintani, Y., & Morii, E. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105048 · Cited by 1
Zhou, X., Sun, J., Miao, L., & Zhang, Y. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1782863 · Cited by 3
Advances in regulatory mechanisms of glycolysis in the pathological process of pulmonary fibrosis
Gao, F., Pu, R., Pan, G., Ma, Y., Zhao, J., Ruohui, W., Cao, X., & Liang, Q. (2026) · European journal of medical research · doi:10.1186/s40001-026-04423-8 · Cited by 1
“Epidemiological data show that idiopathic pulmonary fibrosis (IPF) has an annual incidence of 3–9 cases per 100,000 people, with a median survival time of only 2–3 years after diagnosis and a mortality rate exceeding that of most solid tumors [4, 5].”
Mahapackialakshmi, K., & Jaffino, G. (2026) · Frontiers in Signal Processing · doi:10.3389/frsip.2026.1787092 · Cited by 1
Liu, W. T., Sun, Y., Zhao, L., Wang, S. Y., Zhou, G. F., Wang, S. Y., Xie, S., Geng, J., Xie, B., Ai, W., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03714-2
“Disease progression can be classified into three types: slow progression, rapid progression, and relatively stable stages, with intermittent acute exacerbations [4, 5].”
Liu, T.-W., Zhuang, X.-Y., Chu, M.-H., Wang, Y.-H., Hsieh, Y. S. Y., Hsu, S.-J., Iskandar, B., Lin, S., Wu, H.-H., & Lee, C. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121870
State of the Art: The Relationship Between GERD and Interstitial Lung Disease
Laothamatas, K., McGroder, C. F., & Shah, L. (2026) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161261447971
Objective clinical scoring system and diagnostic variability in idiopathic pulmonary fibrosis
Abecassis, C., Pastré, J., Case, A., et al. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04293-0
“Idiopathic pulmonary fibrosis (IPF), the most common idiopathic interstitial pneumonia, can be challenging to distinguish from other interstitial lung diseases (ILDs) [1, 2].”
Cao, Z., Wei, S., Zhao, Z., Yue, L., Cui, Y., Xu, S., Tan, Z., & Zhai, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00982
Güler, N., Alpaydın, A. Ö., Tertemiz, K. C., Sevinç, C., Ellıdokuz, H., Şimşek, G. Ö., & Uçan, E. S. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04373-1
Gao, Y., Chen, Y., Hu, Z., Wang, Z., Sun, D., Wu, C., Shuai, Q., & Yan, Y. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c05610
Zhang, S.-M., Huang, M.-Z., Wang, Y.-W., Wang, X.-F., Ding, Y., Li, J. Q., Zou, X.-M., & Ma, C. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108946 · Cited by 2
Riccò, B., Grisendi, G., Monaco, A. L., Giuggioli, D., Clini, E. M., & Dominici, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119626 · Cited by 1
Li, B., Xu, R., Zheng, H., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03753-9
“With its diverse manifestations, IPF is a prevalent condition among the elderly, characterized by a poor prognosis, with an average survival time of 3–5 years post-diagnosis [2].”
Baek, I., Park, K., & Kim, K. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70160
Marrocchio, C., & Sverzellati, N. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag324
Mesenchymal stem cells and extracellular vesicles in lung regeneration
Melo, M. M., Santos, R. T., & Silva, J. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45056-3.00004-2
Microbiota-fibroblasts interactions in multi-organ fibrosis
Qi, C., Lin, Z., Gan, Y., Liang, P., Chen, L., Luo, Y., Sweren, E., Alphonse, M. P., Yang, L., Garza, L. A., et al. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128602
Masi, U., Sanduzzi, A., & Zamparelli, S. S. (2026) · Diagnostics · doi:10.3390/diagnostics16132095
“In such contexts, making an accurate diagnosis is not merely a classificatory exercise, but rather a fundamental prerequisite for appropriate prognostic stratification and the implementation of effective therapeutic strategies [1,2].”
Koschel, D., Behr, J., & Bonella, F. (2026) · Pneumologie · doi:10.1055/a-2883-1874
Liang, S., Qin, B., Li, J. N., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146222
“Together, these processes drive disease onset and progression [4–8].”
Lu, G., Ye, P., Wu, F., Lu, Z., Pan, B., Zhuang, P., Zhang, Z., Lyu, C., Nie, W., Zhang, F., et al. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103127
Liu, C., Zhang, Z., Wang, H., Zhang, X., Guan, J., & Mao, S. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179972
Zhang, W., Yuan, L.-L., Li, J.-R., Reiter, R., Zheng, T., Hao, B.-J., & Fan, L. (2026) · Research Square · doi:10.21203/rs.3.rs-10366752/v1
meng, K., Wang, L., Gong, X., Tang, W., Jia, G., Wang, Y., & He, C. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01980-3
“The median survival after diagnosis is only 3 to 5 years, although outcomes vary substantially among patients (Bonella et al. 2023 , Podolanczuk et al. 2023 ).”
Liang, J., Wang, H., Wang, R., et al. (2026) · Die Pharmazie · doi:10.31083/pharmazie52723
Omran, O., Kalra, A., Muelly, M. C., Reicher, J. J., & Ahmed, R. (2026) · Diagnostics · doi:10.3390/diagnostics16152398
Zhao, F., Sun, Y., Wang, H., Hou, D., Zhang, R., Xia, W., 张永臣, Li, L., Zhao, X., Wang, K., et al. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.08.013
Alichubanova, G. E., Makaryants, N. N., & Krakhotkina, A. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-076
Huang, Q., Wang, S., 黄玉满, Xiao, S., Xia, R., & Wang, X. (2026) · Biomolecules · doi:10.3390/biom16081176
Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights
Lou, K. F., Fulcer, M. M., Lotesto, M. J., Davis, J. M., Serrano, T. P. O., Ma, R., & Ridge, K. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0033-2026
Disrupting BRD4-BD1-p62 engagement restores protective autophagy
Zhang, J., Cao, Y., Wu, C., Li, Y., Chen, J., Wang, D., Xiao, Y., Xue, B., Gan, C., Chen, X., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.09.007
Zhu, J., Shen, Y., Yan, Z., You, Z., Chen, L., Zhao, X., Zhou, D., & Li, Y. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101131
Chen, Q., Zhang, Y., Li, J., Zhu, Q., Wang, Z., & Wen, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1934548
“The histopathological hallmark of AE-IPF is DAD superimposed on UIP, a temporally evolving pattern that progresses from early exudative injury to organising and fibroproliferative phases (Podolanczuk et al., 2023).”
Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1873614
Wang, X., Liu, J., & Sang, A. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154515
Kim, M. J., Kwak, H. S., Kim, S., & Kim, H. C. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261484857
“2,3 In addition, patients with IPF have a substantial burden of comorbidities that include both respiratory and non-respiratory diseases, which may further influence clinical outcomes.”
Wilson, J.-A. A. M., Walters, R., Contento, G., Rossanese, M., Guillotin, D., Ward, A. I., Hynds, R. E., Jamal‐Hanjani, M., Kaminski, N., Parolo, S., et al. (2026) · Science Advances · doi:10.1126/sciadv.adx9868 · Cited by 3
“…fibrosis (IPF) represents one the most rapidly progressive and fatal fibrotic conditions with a life expectancy of 3 to 5 years from diagnosis despite the introduction of the first approved antifibrotic agents, pirfenidone and nintedanib, which slow but do not halt disease progression ( 2 – 4 ).”
Liu, Q., Xu, R., & Du, X. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71239
“Antifibrotic therapy is an effective strategy to decelerate disease progression but complications can worsen disease symptoms or promote death [6].”
Tu, Q., Zhang, X., Zou, Y., Lv, Y., Yan, L., Hou, C., Wang, L., Sun, W., Zhang, H., Pan, M., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1884390
“The association between IPF and mortality is well established, with prior studies showing poor prognosis despite antifibrotic treat-ment (4–10, 36).”
The Role of the Nervous System in Lung Disease
Mawer, C. M., Patel, A. J., Zeltner, N., Glassberg, M. K., & Herzog, E. L. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01511-4
“Clinically, it presents with cough, dyspnoea, gas exchange impairment, and frequently progresses to respiratory failure and death [100].”
Ali, A. M. M., Eid, H. A., Moazen, E. M. M., et al. (2026) · Egyptian Journal of Bronchology · doi:10.1186/s43168-026-00678-1
“…and classified into two groups: Group 1 included 32 patients with Idiopathic Pulmonary Fibrosis (IPF), which diagnosed based on ERS guidelines 2023 [19], while Group 2 included 28 patients with Connective Tissue-associated Interstitial Lung Disease (CTD-ILD) based on the recent criteria for…”
RAPA triggers SFN-MDM2/p53 to alleviate pulmonary fibrosis via inhibiting AECII senescencePreprint
Liu, M., Du, B., Xu, Z., Cui, X., Li, Z., Huang, L., & Yuan, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10848894/v1
Wang, Q., Wu, Y., Du, P., Qian, J., Shu, W., Hua, C., & Gao, S. (2026) · Environmental Pollution · doi:10.1016/j.envpol.2026.129254
Bi, W., Zhou, Y., Gong, J., 劉玟儀, Li, J., Du, J., Nie, H., Luo, H., Zhang, H., Cai, Q., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.10.008
Lan, Do, J., Gao, W., Deng, Z., Xia, X., Li, E., Kash, J., Verma, G., Sureshbabu, A., Knox, K. S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.199743
Therapie der Lungenfibrose – Beginn einer neuen Ära
Behr, J., & Veit, T. (2026) · Pneumologie · doi:10.1055/a-2959-4770
Metadata
- Authors
- Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G.
- Affiliations
- Weill Cornell Medicine (US)
- Mount Auburn Hospital (US)
- Università Cattolica del Sacro Cuore (IT)
- St. Joseph’s Healthcare Hamilton (CA)
- University of Washington (US)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2023-01-26
- Volume
- 61
- Issue
- 4
- Pages
- 2200957
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4318071623
- Cited by
- 359
- References
- 196
- Citations by year
- 2026: 112 · 2025: 126 · 2024: 101 · 2023: 20
- FWCI
- 65.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, lung function decline, disease progression, natural history (disease), pathobiology, genetic risk factors, comorbidities, patient monitoring, palliative care, lung transplantation, early detection, diagnosis
- MeSH terms
- Aged, Humans, Tomography, X-Ray Computed, Lung Transplantation, Disease Progression, Early Diagnosis, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.